Analysis of risk factors related to clinical stage in patients with non-small cell lung cancer
10.3969/j.issn.1673-9701.2024.11.005
- VernacularTitle:非小细胞肺癌患者临床分期相关的危险因素分析
- Author:
Songyan ZOU
1
;
Yinyu MU
1
Author Information
1. Clinical Laboratory, Ningbo Medical Center Lihuili Hospital, Ningbo 315040, Zhejiang, China
- Publication Type:Journal Article
- Keywords:
Non-small cell lung cancer;
Clinical stage;
Antinuclear antibody;
Fibrinogen;
Cytokeratin 19 fragment
- From:
China Modern Doctor
2024;62(11):18-21
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the risk factors associated with clinical stage in patients with non-small cell lung cancer(NSCLC).Methods The clinical data of 182 patients with non-small cell lung cancer admitted from July 2019 to March 2023 were retrospectively analyzed,and they were divided into stage Ⅰ,stage Ⅱ group(n=73)and stage Ⅲ,stage Ⅳ group(n=109)according to the clinical stage.Inter-group comparison and Logistic regression analysis were used to screen the risk factors affecting the clinical stage of patients,and receiver operating characteristic(ROC)curve was used to analyze the diagnostic value of these risk factors.Results Antinuclear antibody(ANA),fibrinogen(FIB)and cytokeratin 19 fragment(CYFRA21-1)were independent risk factors affecting the clinical stage of NSCLC patients.The optimal cut-off values of FIB and CYFRA21-1 were 4.07g/L and 7.07μg/L,respectively.The area under curve(AUC)of the combined diagnosis of clinical stage was 0.859,the sensitivity was 64.2％,and the specificity was 95.9％.Conclusion ANA,FIB and CYFRA21-1 are independent risk factors for the progression of clinical stage of NSCLC patients.The combined detection of the three indicators has certain reference value for the diagnosis of clinical stage in NSCLC patients.
